Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers Meeting Abstract
| Authors: | Sanborn, R.; Gabrail, N.; O'Hara, M.; Bhardwaj, N.; Gordon, M.; Hauke, R.; Bordoni, R.; Khalil, D.; Rawls, T.; Vitale, L.; Gedrich, R.; Hawthorne, T.; Keler, T.; Forsberg, E.; Thomas, L.; Yellin, M. |
| Abstract Title: | Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers |
| Meeting Title: | 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 7 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Nov 6-10 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2019-11-01 |
| Start Page: | 283 |
| Language: | English |
| ACCESSION: | WOS:000496473200322 |
| PROVIDER: | wos |
| PMCID: | PMC6833180 |
| PUBMED: | 31694708 |
| DOI: | 10.1186/s40425-019-0764-0 |
| Notes: | Meeting Abstract: P827 -- Source: Wos |
